LMS increases the diagnosis and follow-up quality, which is good for the radiologists and of course patients, and the oncologists love the automatic report that is generated...

Pr. Philippe Peetrons
IRIS South Hospitals, Brussels, Belgium

Using LMS-Liver makes comparison studies less tedious for radiologists and ensures the oncologists and patients that such studies are carried out properly.

Pr. Olivier Lucidarme
La Pitié-Salpêtrière Hospital - Paris, France
 

11/26/09 - Chicago, IL, USA

MEDIAN Technologies Unveils Latest Developments of Lesion Management Solutions at RSNA 2009

MEDIAN Technologies latest developments allow users within the same application to evaluate, follow and report the evolution of cancerous lesions visible on CT images covering the neck to pelvis area. MEDIAN LMS generates a single report for the quantitat

 
 
/ Home
/ Target Audience

Pharmaceutical Companies

Target Audience:Pharmaceutical Companies

Pharmaceutical Companies need to monitor trial results in real time at all participating sites to take earlier “Go” or “No Go” decisions.

  • LMS provides centralized data management with unique multi-site integration capabilities to store all lesion measures and make them available at all times.
  • Lesion measures stored in the centralized data management system can then be correlated with other functional or anatomical information.

 

Regulatory authorities require pharmaceutical companies to conform to international criteria such as RECIST to evaluate drug effectiveness.

  • LMS automatically generates reports according to RECIST criteria.
  • LMS provides automatic and consistent quantification of lesion growth to limit discordance.

 

Lesion volume and attenuation changes bring additional value to assess molecule behavior and drug effectiveness.

  • LMS provides volume growth and attenuation values and histogram.
  • Volume and attenuation values and changes are stored in the centralized data management system along with diameter information.